Clinical Outcomes of Oral Anticoagulant Discontinuation in Atrial Fibrillation: a Systematic Review and Meta-Analysis

Introduction Oral anticoagulants (OACs) should generally be continued lifelong in patients with atrial fibrillation (AF) to ensure optimal benefits, unless contraindications arise. However, discontinuation of OACs might occur for various reasons, potentially affecting clinical outcomes. In this review, we synthesized evidence on the clinical outcomes following OAC discontinuation in patients with AF.Methods We conducted a systematic review and meta-analysis using PubMed, Embase and Scopus. Cohort or case–control studies were included if data were available on clinical outcomes of OAC discontinuation, compared with continuation, in patients with AF. A random-effect meta-analyses were conducted for key outcomes of stroke, mortality, and major bleeding.Results Eighteen observational studies having a total of 283,418 patients were included. Discontinuation significantly increased the risk of stroke (hazard ratio [HR] 1.88; 95% confidence interval [CI] 1.58–2.23), all-cause (HR 1.90; 95% CI 1.40–2.59) and cardiovascular (HR 1.83; 95% CI 1.06–3.18) mortality. The risk of major bleeding was not significantly different between the discontinued and continued groups (HR 1.04; 95% CI 0.72–1.52).Conclusions Discontinuation of OAC therapy was associated with an increased risk of stroke and mortality, with no difference in the risk of major bleeding. Acknowledging heterogeneity among the studies, the findings underline the need to ensure continuity of OAC therapy in patients with AF to prevent thrombotic complications and associated mortality.PROSPERO registration number CRD42020186116